Swedish National Registry of Urinary Bladder Cancer: No difference in relative survival over time despite more aggressive treatment

References

• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374–403.
   PubMed Web of Science ®Google Scholar
• Gårdmark T, Bladström A, Hellsten S, Malmström P-U. Members of the Swedish National Bladder Cancer Registry. Analysis of clinical characteristics, management and survival of patients with Ta, T1 bladder tumours in Sweden between 1997 and 2001. Scand J Urol Nephrol 2006;40:276–82.
   PubMed Web of Science ®Google Scholar
• Holmäng S, Hedelin H, Anderström C, Johansson SL. Long-term follow-up of patients with muscle invasive (stages T2, T3 and T4) bladder carcinoma in a geographical region. J Urol 1997;158:389–92.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO) Consensus Conference on Bladder Cancer. Hautmann RE, Abol-Enein H, Hafez K, Haro I, Månsson W, Mills RD, et al. Urinary diversion. Urology 2007;69:17–49.
   Web of Science ®Google Scholar
• Snyder C, Harlem L, Knopf K, Potosky A, Kaplan R. Patterns of care for the treatment of bladder cancer. J Urol 2003;169:1697–701.
   PubMed Web of Science ®Google Scholar
• Prout GR, Welsey MN, Yannick R, Ries LA, Havlik RJ, Edwards BK. Age and comorbidity impact surgical therapy in older bladder cancer patients: a population-based study. Cancer 2005;104:1638–47.
   PubMed Web of Science ®Google Scholar
• Puente D, Malats N, Cecchini L, Tardón A, García-Closas R, Serra C, et al. Gender-related differences in clinical and pathological characteristics and therapy of bladder cancer. Eur Urol 2003;43:53–62.
   PubMed Web of Science ®Google Scholar
• Konety BR, Joslyn SA. Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol 2003;170:1765–71.
   PubMed Web of Science ®Google Scholar
• Jahnson S, Månsson W, Hellsten S, Liedberg F, Damm O, Holmäng S, et al. Patterns of care for muscle invasive bladder cancer in Sweden – a population-based study. Scand J Urol Nephrol 2009;43:271–6.
   PubMed Web of Science ®Google Scholar
• Jahnson S, Månsson W, Hellsten S, Liedberg F, Damm O, Holmäng S, et al. Urinary diversion after cystectomy for bladder cancer: a population-based study in Sweden. Scand J Urol Nephrol 2010;44:69–75.
   PubMed Web of Science ®Google Scholar
• Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol 2013;37:219–25.
   PubMed Web of Science ®Google Scholar
• Kamel MH, Moore PC, Bissada NK, Heshmat SM. Potential years of life due to urogenital cancer in the United States. Trends from 1972 to 2006 based on data from the SEER database. J Urol 2012;187:868–71.
   PubMed Web of Science ®Google Scholar
• Malmström PU, Thörn M, Lindblad P, Bergström R, Adami HO. Increasing survival of patients with urinary bladder cancer. A nationwide study in Sweden 1960–1986. Eur J Cancer 1993;29A:1868–72.
   PubMed Web of Science ®Google Scholar
• Hermanek P, Sobin LH. editors. TNM classification of malignant tumours. 4th edition. Berlin: Springer; 1987.
   Google Scholar
• Sobin LH, Wittekind CH. editors. TNM classification of malignant tumours. 5th edition. New York: Wiley-Liss; 1997.
   Google Scholar
• Sobin LH, Wittekind CH. editors. TNM classification of malignant tumours. 6th edition. New York: Wiley-Liss; 2004.
   Google Scholar
• Sobin LH, Wittekind CH. editors. TNM classification of malignant tumours. 7th edition. New York: Wiley-Liss; 2009.
   Google Scholar
• Shah A, Rachet B, Mitry E, Cooper N, Brown CM, Coleman MP. Survival from bladder cancer in England and Wales up to 2001. Br J Cancer 2008;99:86–9.
   PubMed Web of Science ®Google Scholar
• Lund L, Erichsen R, Nørgaard M, Larsen EH, Borre M, Jacobsen J. Survival of invasive bladder cancer patients, 1998–2009; a central and northern Denmark population-based cohort study. Clin Epidemiol 2011;3:47–51.
   PubMedGoogle Scholar
• Hollenbeck BK, Miller DC, Taub D, Dunn RL, Underwood W, Montie JE, et al. Aggressive treatment bladder cancer is associated with improved overall survival among patients 80 years or older. Urology 2004;64:292–7.
   PubMed Web of Science ®Google Scholar
• Noon AP, Albertsen PC, Thomas F, Rosario DJ, Catto JWF. Competing mortality in patients diagnosed with bladder cancer: evidence of under-treatment in the elderly and female patients. Br J Cancer 2013;108:1534–40.
   PubMed Web of Science ®Google Scholar
• Schrag D, Mitra N, Xu F, Rabbani F, Bach PB, Herr H, et al. Cystectomy for muscle-invasive bladder cancer: patterns of care and outcomes of care in the Medicare population. Urology 2005;65:1118–25.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette–Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964–70.
   PubMed Web of Science ®Google Scholar
• Madeb R, Golijanin D, Noyes K, Fisher S, Stephenson JJ, Long SR, et al. Treatment of non-muscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer 2009;115:2660–70.
   PubMed Web of Science ®Google Scholar
• Witjes AJ, Palou J, Soloway M, Lamm D, Kamat AM, Brausi M, et al. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette Guérin (BCG): results of an international individual patient data survey (IPDS). BJU Int 2013;112:742–50.
   PubMed Web of Science ®Google Scholar
• Chamie K, Saigal C, Lai J, Hanley JM, Setodji CM, Konety BR, et al. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer 2011;117:5392–401.
   PubMed Web of Science ®Google Scholar
• Strope SA, Ye Z, Hollingsworth JM, Hollenbeck BK. Patterns of care for early stage bladder cancer. Cancer 2010;116:2604–11.
   PubMed Web of Science ®Google Scholar
• Huang GJ, Hamilton AS, Lo M, Stein JP, Penson DF. Predictors of intravesical therapy use in nonmuscle invasive bladder cancer: results from the Surveillance, Epidemiology and End Results Program 2003 Patterns of Care Project. J Urol 2008;180:520–52.
   PubMed Web of Science ®Google Scholar
• Nielsen ME, Smith AB, Meyer AM, Kuo TM, Tyree S, Kim WY, et al. Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006. Cancer 2014;120:86–95.
   PubMed Web of Science ®Google Scholar
• Schend AR, Andrew AS, Marsit C, Kelsey KT, Zens MS, Karagaz MR. Histological classification and stage of newly diagnosed bladder cancer in a population-based study from the Northeastern United States. Scand J Urol Nephrol 2008;42:237–42.
   PubMed Web of Science ®Google Scholar
• Gore JL, Saigal CS, Handley JM, Litwin MS. Variations in reconstruction after radical cystectomy. Cancer 2006;107:729–37.
   PubMed Web of Science ®Google Scholar
• Kim SP, Shah ND, Weight CJ, Thompson RH, Wang JK, Karnes RJ, et al. Population-based trends in urinary diversion among patients undergoing radical cystectomy for bladder cancer. BJU Int 2013;112:478–84.
   PubMed Web of Science ®Google Scholar